Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Revolution Medicines (RVMD) Operating Expenses (2019 - 2025)

Revolution Medicines has reported Operating Expenses over the past 7 years, most recently at $361.6 million for Q4 2025.

  • Quarterly results put Operating Expenses at $361.6 million for Q4 2025, up 67.18% from a year ago — trailing twelve months through Dec 2025 was $1.2 billion (up 71.48% YoY), and the annual figure for FY2025 was $1.2 billion, up 71.48%.
  • Operating Expenses for Q4 2025 was $361.6 million at Revolution Medicines, up from $315.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for RVMD hit a ceiling of $361.6 million in Q4 2025 and a floor of $47.5 million in Q1 2021.
  • Median Operating Expenses over the past 5 years was $117.9 million (2023), compared with a mean of $144.1 million.
  • Biggest five-year swings in Operating Expenses: soared 134.6% in 2023 and later increased 19.69% in 2024.
  • Revolution Medicines' Operating Expenses stood at $62.4 million in 2021, then rose by 23.51% to $77.0 million in 2022, then soared by 134.6% to $180.7 million in 2023, then rose by 19.69% to $216.3 million in 2024, then surged by 67.18% to $361.6 million in 2025.
  • The last three reported values for Operating Expenses were $361.6 million (Q4 2025), $315.3 million (Q3 2025), and $264.7 million (Q2 2025) per Business Quant data.